Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) butedronic acid
- Development stage
- Unknown
- Lead developer
- Curium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
technetium (99mTc) butedronic acid (also known as technetium-99m-3,3-diphosphono-1,2-propanedicarboxylic acid or 99mTc-DPD) is a diagnostic radiopharmaceutical used in nuclear medicine. It is a bone-seeking bisphosphonate tracer that binds with high affinity to hydroxyapatite crystals in areas of active bone remodeling. Reconstituted from a cold kit (marketed under the brand name Teceos), it is primarily indicated for bone scintigraphy to detect skeletal metastases, trauma, and degenerative bone diseases. Additionally, 99mTc-DPD has emerged as a key non-invasive diagnostic tool for transthyretin cardiac amyloidosis (ATTR-CA), where it accumulates in myocardial amyloid deposits, allowing clinicians to confirm ATTR-CA with high accuracy without the need for endomyocardial biopsy.
- Brand names
- Teceos
- Other names
- 99mTc-3,3-diphosphono-1,2-propanedicarboxylic acid99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid99mTc-dicarboxypropane diphosphonate99mTc-DPDbutedronatebutedronate tetrasodiumbutedronic acidtechnetium (99mTc) butedronatetechnetium Tc 99m butedronatetechnetium-99m-3,3-diphosphono-1,2-propanedicarboxylic acid
Beyond the preview
Go deeper on technetium (99mTc) butedronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) butedronic acid.